Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspire-201 of AHB-137 in nucleos(t)ide analogue-treated HBeAg-negative chronic hepatitis B
jRCT2031260390Phase 2Recruiting
- Sponsor
- AusperBio
- Start
- Sep 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, open-label trial of AHB-137 in Chronic Hepatitis B (CHB) (2 arms), sponsored by AusperBio. Primary endpoint: Proportion of participants with sustained response post AHB-137 treatment. Started Sep 2026; status: recruiting.
02
Drugs
AHB-137
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2031260390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260390.